Related Experiment Video
Updated: Apr 29, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Management of metastatic castration-resistant prostate cancer
1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Abstract:
The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forward in the last 2 years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel, and abiraterone acetate), and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are demonstrating preliminary signs of clinical benefit, leading to more definitive phase III confirmatory trials. In this review, we will discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options for these patients. Knowledge of these evolving standards will help to optimize delivery of care and long term outcomes in men with advanced CRPC.
Insights
Recent advancements offer new treatments for metastatic castration-resistant prostate cancer (CRPC), improving survival and delaying bone issues. This review covers approved and emerging options to optimize care for advanced CRPC patients.
Area of Science:
- Oncology
- Urology
- Medical Oncology
Background:
- Metastatic castration-resistant prostate cancer (CRPC) management has evolved significantly.
- Recent years have seen breakthroughs in systemic therapies and bone-targeted agents.
Purpose of the Study:
- To review the current and emerging treatment landscape for men with CRPC.
- To highlight novel agents improving overall survival and delaying skeletal-related events.
- To guide the optimization of care for advanced CRPC.
Main Methods:
- Review of recent clinical trial data and approved therapies for CRPC.
- Analysis of novel agents with diverse mechanisms of action.
- Focus on treatments demonstrating improved overall survival and skeletal event delay.
Main Results:
- Sipuleucel-T, cabazitaxel, and abiraterone acetate show improved overall survival in CRPC.
- Denosumab significantly delays skeletal-related events in CRPC patients.
- Multiple new agents in the pipeline show preliminary clinical benefit.
Conclusions:
- The treatment of advanced CRPC is rapidly evolving with new therapeutic options.
- Understanding these advancements is crucial for improving patient outcomes.
- Ongoing research continues to strengthen the pipeline of systemic therapies for prostate cancer.
